Germany
The revised EU Urban Wastewater Treatment Directive, which obliges pharmaceutical and cosmetic industries to contribute at least 80% towards the costs of removing micropollutants from wastewater through quaternary treatments, will place an additional burden of around €2bn per year on German manufacturers, says Pharma Deutschland.
In this third article of a series on new drug reimbursement recommendations by the HTA body NICE, the Pink Sheet finds that fewer innovative medicines are reimbursed in England than in eight other European nations.
A new act in Germany does not go far enough to address the deeply unpopular “guardrail” link between Amnog benefit assessment ratings and price negotiations, which can deter companies from launching.
J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.
Adult immunization programs can save “billions” for society, but their value is underestimated because of challenges around measuring broader value evidence and a lack of incentives for companies to collect this data, says the Office of Health Economics.
The European Parliament has voted for a deal agreed with the council of ministers to ensure polluters pay for cleaning up urban wastewater.
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Pharmaceutical companies, NGOs, and patient organizations were among the 129 respondents to the European Commission’s consultation on its draft implementing act for joint clinical assessments – but opinions on the proposal were divided.
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.
Industry is wary of a provision in Germany’s medical research bill that would introduce standard clauses in the contracts agreed between trial sponsors and study sites.
Better data linkage and data entry systems could transform Germany’s clinical cancer registries into a reliable data source for health technology assessments.
Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.
Sanofi says it will engage further with NICE after the health technology assessment body rejected Sarclisa for previously-treated multiple myeloma, and that it is “hopeful a way forward can be found.”
A revised benefit rating for BMS’ cardiomyopathy drug Camzyos will be good news for the product’s pricing in Germany.
Patients in England with relapsed or refractory diffuse large B-cell lymphoma will have another treatment option after the health technology appraisal institute NICE recommended AbbVie’s bispecific antibody Tepkinly for funding on the National Health Service . The product is also undergoing a benefit assessment in Germany.
Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.
The move is intended to boost German innovation in the pharmaceutical area, but some say the impact of the strategy remains “uncertain.”
Pfizer’s Talzenna is soon to be made available to National Health Service patients in England and Wales with HER2-negative advanced breast cancer with inherited BRCA mutations, after the company agreed to provide the PARP inhibitor at a larger discount than it originally offered.